The use of ustekinumab and guselkumab in a pediatric psoriasis patient with active hepatitis B infection.
作者信息
Song Eingun James, Whitman Patrick, Samsel Jonmichael
机构信息
North Sound Dermatology, Mill Creek, Washington.
Silver Falls Dermatology, Salem, Oregon.
出版信息
JAAD Case Rep. 2020 Dec 14;8:37-39. doi: 10.1016/j.jdcr.2020.12.006. eCollection 2021 Feb.
Abstract
摘要
相似文献
1
The use of ustekinumab and guselkumab in a pediatric psoriasis patient with active hepatitis B infection.优特克单抗和古塞库单抗在一名患有活动性乙型肝炎感染的儿童银屑病患者中的应用。
JAAD Case Rep. 2020 Dec 14;8:37-39. doi: 10.1016/j.jdcr.2020.12.006. eCollection 2021 Feb.
2
The use of interleukin 23 inhibitors in patients with chronic hepatitis B infection: A case series.白细胞介素23抑制剂在慢性乙型肝炎感染患者中的应用：病例系列
JAAD Case Rep. 2022 Oct 4;30:1-4. doi: 10.1016/j.jdcr.2022.09.023. eCollection 2022 Dec.
3
Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double-blind, phase III NAVIGATE trial.古塞库单抗治疗乌司奴单抗应答不足的银屑病患者的疗效和安全性：随机、双盲、III 期 NAVIGATE 试验结果。
Br J Dermatol. 2018 Jan;178(1):114-123. doi: 10.1111/bjd.15750. Epub 2017 Oct 10.
4
The safety profile of ustekinumab in the treatment of patients with psoriasis and concurrent hepatitis B or C.乌司奴单抗治疗银屑病合并乙型或丙型肝炎患者的安全性特征。
Br J Dermatol. 2013 Dec;169(6):1295-303. doi: 10.1111/bjd.12461.
5
Guselkumab: A Review in Moderate to Severe Plaque Psoriasis.古塞库单抗：治疗中重度斑块状银屑病的研究进展。
Am J Clin Dermatol. 2018 Dec;19(6):907-918. doi: 10.1007/s40257-018-0406-1.
6
Safety of guselkumab in hepatitis B virus infection.古塞库单抗在乙型肝炎病毒感染中的安全性。
Dermatol Online J. 2019 Oct 15;25(10):13030/qt47h636rx.
7
Treating Moderate-to-Severe Plaque Psoriasis With Guselkumab: A Review of Phase II and Phase III Trials.使用古塞库单抗治疗中重度斑块状银屑病：II期和III期试验综述
Ann Pharmacother. 2018 Apr;52(4):380-387. doi: 10.1177/1060028017743268. Epub 2017 Nov 14.
8
Managing Psoriasis in Patients with HBV or HCV Infection: Practical Considerations.管理乙肝或丙肝感染患者的银屑病：实用注意事项。
Am J Clin Dermatol. 2019 Dec;20(6):829-845. doi: 10.1007/s40257-019-00457-3.
9
Safety and effectiveness of ustekinumab and antitumour necrosis factor therapy in patients with psoriasis and chronic viral hepatitis B or C: a retrospective, multicentre study in a clinical setting.在临床环境中进行的一项回顾性、多中心研究：乌司奴单抗和抗肿瘤坏死因子治疗对银屑病合并慢性乙型或丙型肝炎病毒患者的安全性和有效性。
Br J Dermatol. 2013 Mar;168(3):609-16. doi: 10.1111/bjd.12045.
10
Two cases of hepatitis B in patients with moderate to severe psoriasis with ustekinumab.
J Drugs Dermatol. 2012 Dec;11(12):1498-501.
引用本文的文献
1
Guselkumab - In Psoriasis and Beyond.古塞库单抗——用于银屑病及其他病症
Dermatol Pract Concept. 2024 Jul 1;14(3):e2024181. doi: 10.5826/dpc.1403a181.
2
Management Strategies for Pediatric Moderate-to-Severe Plaque Psoriasis: Spotlight on Biologics.儿童中重度斑块状银屑病的管理策略：聚焦生物制剂
Pediatric Health Med Ther. 2023 Nov 14;14:435-451. doi: 10.2147/PHMT.S389108. eCollection 2023.
3
Efficacy and Safety of Tildrakizumab in a Patient with Chronic HBV Infection.替拉珠单抗治疗慢性乙型肝炎病毒感染患者的疗效和安全性
Clin Cosmet Investig Dermatol. 2023 Feb 5;16:369-373. doi: 10.2147/CCID.S403294. eCollection 2023.
4
Anti-IL23 biologic therapies in the treatment of psoriasis: real-world experience versus clinical trials data.抗白细胞介素 23 生物制剂治疗银屑病：真实世界经验与临床试验数据对比。
Immunol Res. 2023 Jun;71(3):328-355. doi: 10.1007/s12026-022-09356-y. Epub 2023 Jan 4.
5
The use of interleukin 23 inhibitors in patients with chronic hepatitis B infection: A case series.白细胞介素23抑制剂在慢性乙型肝炎感染患者中的应用：病例系列
JAAD Case Rep. 2022 Oct 4;30:1-4. doi: 10.1016/j.jdcr.2022.09.023. eCollection 2022 Dec.
6
Novel Therapeutic Approaches to Psoriasis and Risk of Infectious Disease.银屑病的新型治疗方法与传染病风险
Biomedicines. 2022 Jan 21;10(2):228. doi: 10.3390/biomedicines10020228.
本文引用的文献
1
Safety of guselkumab in hepatitis B virus infection.古塞库单抗在乙型肝炎病毒感染中的安全性。
Dermatol Online J. 2019 Oct 15;25(10):13030/qt47h636rx.
2
An interleukin-17 inhibitor successfully treated a complicated psoriasis and psoriatic arthritis patient with hepatitis B virus infection and end-stage kidney disease on hemodialysis.一种白细胞介素-17抑制剂成功治疗了一名患有乙型肝炎病毒感染和终末期肾病且正在接受血液透析的复杂银屑病和银屑病关节炎患者。
JAAD Case Rep. 2019 Jan 25;5(2):150-152. doi: 10.1016/j.jdcr.2018.11.016. eCollection 2019 Feb.
3
Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double-blind, phase III NAVIGATE trial.古塞库单抗治疗乌司奴单抗应答不足的银屑病患者的疗效和安全性：随机、双盲、III 期 NAVIGATE 试验结果。
Br J Dermatol. 2018 Jan;178(1):114-123. doi: 10.1111/bjd.15750. Epub 2017 Oct 10.
4
Management of psoriasis patients with hepatitis B or hepatitis C virus infection.乙型或丙型肝炎病毒感染的银屑病患者的管理。
World J Gastroenterol. 2016 Jul 28;22(28):6444-55. doi: 10.3748/wjg.v22.i28.6444.
5
Hepatitis B virus reactivation in HBsAg-positive patients with rheumatic diseases undergoing anti-tumor necrosis factor therapy or DMARDs.HBsAg 阳性的风湿性疾病患者在接受抗肿瘤坏死因子治疗或 DMARDs 治疗时乙型肝炎病毒再激活。
Int J Rheum Dis. 2013 Oct;16(5):527-31. doi: 10.1111/1756-185X.12154.
6
The safety profile of ustekinumab in the treatment of patients with psoriasis and concurrent hepatitis B or C.乌司奴单抗治疗银屑病合并乙型或丙型肝炎患者的安全性特征。
Br J Dermatol. 2013 Dec;169(6):1295-303. doi: 10.1111/bjd.12461.
7
Safety and effectiveness of ustekinumab and antitumour necrosis factor therapy in patients with psoriasis and chronic viral hepatitis B or C: a retrospective, multicentre study in a clinical setting.在临床环境中进行的一项回顾性、多中心研究：乌司奴单抗和抗肿瘤坏死因子治疗对银屑病合并慢性乙型或丙型肝炎病毒患者的安全性和有效性。
Br J Dermatol. 2013 Mar;168(3):609-16. doi: 10.1111/bjd.12045.
8
Tumor necrosis factor blockade and the risk of viral infection.肿瘤坏死因子阻断与病毒感染风险。
Nat Rev Rheumatol. 2010 Mar;6(3):165-74. doi: 10.1038/nrrheum.2009.279. Epub 2010 Feb 9.
9
Hepatitis B virus (HBV) reactivation with immunosuppressive therapy in rheumatic diseases: assessment and preventive strategies.风湿性疾病中免疫抑制治疗导致的乙型肝炎病毒（HBV）再激活：评估与预防策略
Ann Rheum Dis. 2006 Aug;65(8):983-9. doi: 10.1136/ard.2005.043257. Epub 2006 Apr 20.
Zotero 插件